Skip to main content

Design Therapeutics, Inc.

DSGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001807120

No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Design Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of DSGN: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders9395+2
Shares30.7M32.1M+1.37M (+4.5%)
Value$123.9M$107.5M−$16.4M (−13.2%)

New holders (15)

Institutions that held Design Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to DSGN in Q2 2024
InstitutionSharesValue% of portfolio
Frazier Life Sciences Management, L.P.1,195,179$4.00M0.19%
Jane Street Group, LLC57,905$194.0K0.00%
Caz Investments LP40,000$134.0K0.20%
PDT Partners, LLC27,127$90.9K0.01%
Verition Fund Management LLC27,045$90.6K0.00%
Marshall Wace, LLP24,280$81.3K0.00%
American Century Companies Inc21,333$71.5K0.00%
Jump Financial, LLC20,087$67.3K0.00%
Corebridge Financial, Inc.16,892$56.6K0.00%
Mirae Asset Global ETFs Holdings Ltd.16,270$54.5K0.00%
Virtu Financial LLC11,070$37.0K0.00%
Qube Research & Technologies Ltd2,986$10.0K0.00%
Point72 Asia (Singapore) Pte. Ltd.1,288$4.32K0.00%
SRS Capital Advisors, Inc.244$8180.00%
Principal Securities, Inc.74$2480.00%

Sold out (13)

Institutions that held Design Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.